Ingelheim, Germany/Ridgefield, Connecticut, U.S. * Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.(1) * Approval is based on results from two clinical trials, which showed reduction in Forced Vital Capacity decline with JASCAYD versus placebo in adults with idiopathic pulmonary fibrosis (IPF).(2,3) * Nerandomilast is a new treatment option for adult patients with IPF with a well-tolerated safety profile.(2,3) Boehringer Ingelheim's...